13. 多発性硬化症／視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04025554 (ClinicalTrials.gov) | October 25, 2019 | 18/7/2019 | Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis | Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis | Multiple Sclerosis | Drug: Anakinra | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Recruiting | 18 Years | N/A | All | 10 | Phase 1/Phase 2 | United States |